Alveolar inflammation in cystic fibrosis

Journal of Cystic Fibrosis

Volumn 9, Issue 3, 2010, Pages 217-227

  Ulrich, Martina ^a   Worlitzsch, Dieter ^a,b   Viglio, Simona ^c   Siegmann, Nanna ^a   Iadarola, Paolo ^c   Shute, Janis K ^d   Geiser, Marianne ^e   Pier, Gerald B ^f   Friedel, Godehard ^g   Barr, Mark L ^h   Schuster, Antje ⁱ   Meyer, Keith C ^j   Ratjen, Felix ^k   Bjarnsholt, Thomas ^l   Gulbins, Erich ^m   Döring, Gerd ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^e UNIVERSITY OF BERN   (Switzerland)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g Lungenfachklinik Schillerhöhe   (Germany)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ HEINRICH HEINE UNIVERSITY   (Germany)

^j UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^k HOSPITAL FOR SICK CHILDREN   (Canada)

^l UNIVERSITY OF COPENHAGEN   (Denmark)

^m UNIVERSITY OF DUISBURG ESSEN   (Germany)

more..

Author keywords

Ceramide; Collagen; Elastin; Macrophages; Neutrophils; Pathophysiology

Indexed keywords

CERAMIDE; COLLAGEN; DESMOSINE; ELASTASE; ELASTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; ISODESMOSINE; SOMATOMEDIN C; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADAPTIVE IMMUNITY; ARTICLE; CELL INFILTRATION; CELL TYPE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INNATE IMMUNITY; LUNG ALVEOLITIS; MACROPHAGE; MYOFIBROBLAST; NEUTROPHIL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; T LYMPHOCYTE; URINALYSIS; ADOLESCENT; ADULT; CASE CONTROL STUDY; FEMALE; IMMUNOLOGY; INFLAMMATION; ISOLATION AND PURIFICATION; LUNG ALVEOLUS; MALE; METABOLISM; MICROBIOLOGY; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CERAMIDES; COLLAGEN; CYSTIC FIBROSIS; DESMOSINE; ELASTIN; FEMALE; HUMANS; INFLAMMATION; ISODESMOSINE; MALE; PSEUDOMONAS AERUGINOSA; PULMONARY ALVEOLI; YOUNG ADULT;

EID: 77953357622     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2010.03.001     Document Type: Article

References (56)

1. Rommens J.M., Iannuzzi M.C., Kerem B., Drumm M.L., Melmer G., Dean M., Rozmahel R., Cole J.L., Kennedy D., Hidaka N., Zsiga M., Buchwald M., Riordan J.R., Tsui L.-C., Collins F. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989, 245:1059-1065.
2. Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., Zielenski J., Lok S., Plavsic N., Chou J.L., Drumm M.L., Iannuzzu M.C., Collins F.S., Tsui L.-C. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245:1066-1073.
3. Kerem B., Rommens J.M., Buchanan J.A., Markiewicz D., Cox T.K., Chakravarti A., Buchwald M., Tsui L.-C. Identification of the cystic fibrosis gene: genetic analysis. Science 1989, 245:1073-1080.
4. Boucher R.C. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004, 23:146-158.
5. Worlitzsch D., Tarran R., Ulrich M., Schwab U., Cekici A., Meyer K.C., Birrer P., Bellon G., Berger J., Weiß T., Botzenhart K., Yankaskas J.R., Randell S., Boucher R.C., Döring G. Reduced oxygen concentrations in airway mucus contribute to the early and late pathogenesis of Pseudomonas aeruginosa cystic fibrosis airways infection. J Clin Invest 2002, 109:295-309.
6. Döring G., Knight R., Bellon G. Immunology of cystic fibrosis. cystic fibrosis 2000, 109-141. Arnold, London, England. M.E. Hodson, D. Geddes (Eds.).
7. Hogg J.C., Senior R.M. Chronic obstructive pulmonary disease - part 2: pathology and biochemistry of emphysema. Thorax 2002, 57:830-834.
8. Sobonya R.E., Taussig L.M. Quantitative aspects of lung pathology in cystic fibrosis. Am Rev Respir Dis 1986, 134:290-295.
9. Bedrossian C.W.M., Greenberg S.D., Singer D.B., Hansen J.J., Rosenberg H.S. The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Human Pathol 1976, 7. 195-04.
10. Tiddens H.A., Koopman L.P., Lambert R.K., Elliott W.M., Hop W.C., van der Mark T.W., de Boer W.J., de Jongste J.C. Cartilaginous airway wall dimensions and airway resistance in cystic fibrosis lungs. Eur Respir J 2000, 15:735-742.
11. Durieu I., Peyrol S., Gindre D., Bellon G., Durand D.V., Pacheco Y. Subepithelial fibrosis and degradation of the bronchial extracellular matrix in cystic fibrosis. Am J Respir Crit Care Med 1998, 158:580-588.
12. Shute J., Marshall L., Bodey K., Bush A. Growth factors in cystic fibrosis - when more is not enough. Paediatr Respir Rev 2003, 4:120-127.
13. Ratjen F., Döring G. Cystic fibrosis. Lancet 2003, 361:681-689.
14. Hamutcu R., Rowland J.M., Horn M.V., Kaminsky C., MacLaughlin E.F., Starnes V.A., Woo M.S. Clinical findings and lung pathology in children with cystic fibrosis. Am J Respir Crit Care Med 2002, 165:1172-1175.
15. - channel function. Am J Physiol Lung Cell Mol Physiol 2001, 281:L71-L78.
16. Joseph T., Look D., Ferkol T. NF-kappaB activation and sustained IL-8 gene expression in primary cultures of cystic fibrosis airway epithelial cells stimulated with Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol 2005, 288:L471-L479.
17. Tabary O., Escotte S., Couetil J.P., Hubert D., Dusser D., Puchelle E., Jacquot J. Relationship between IkappaBalpha deficiency, NFkappaB activity and interleukin-8 production in CF human airway epithelial cells. Pflugers Archiv - Eur J Physiol 2001, 443(Suppl 1). S40-S4.
18. Teichgräber V., Ulrich M., Riethmüller J., Grassme H., Wilker B., De Oliveira-Munding C.C., van Heeckeren A.M., Barr M., von Kürthy G., Schmid K.W., Weller M., Tümmler B., Lang F., Döring G., Gulbins E. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nature Med 2008, 14:381-392.
19. Kreda S.M., Mall M., Mengos A., Rochelle L., Yankaskas J., Riordan J.R., Boucher R.C. Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia. Mol Biol Cell 2005, 16:2154-2167.
20. Regnier A., Dannhoffer L., Blouquit-Laye S., Bakari M., Naline E., Chinet T. Expression of cystic fibrosis transmembrane conductance regulator in the human distal lung. Human Pathol 2008, 39:368-376.
21. Johnson M.D., Bao H.F., Helms M.N., Chen X.J., Tigue Z., Jain L., Dobbs L.G., Eaton D.C. Functional ion channels in pulmonary alveolar type I cells support a role for type I cells in lung ion transport. PNAS 2006, 103:4964-4969.
22. PBJr McCray, Wohlford-Lenane C.L., Snyder J.M. Localization of cystic fibrosis transmembrane conductance regulator mRNA in human fetal lung tissue by in situ hybridization. J Clin Invest 1992, 90:619-625.
23. Fang X., Song Y., Hirsch J., Galietta L.J., Pedemonte N., Zemans R.L., Dolganov G., Verkman A.S., Matthay M.A. Contribution of CFTR to apical-basolateral fluid transport in cultured human alveolar epithelial type II cells. Am J Physiol Lung Cell Mol Physiol 2006, 290:L242-L249.
24. Viglio S., Iadarola P., Lupi A., Trisolini R., Tinelli C., Balbi Grassi V., Worlitzsch D., Döring G., Meloni F., Meyer K.C., Dowson L., Hill S.L., Stockley R.A., Luisetti M. MEKC of desmosine and isodesmosine in urine of chronic destructive lung disease patients. Eur Respir J 2000, 15:1039-1045.
25. Grassme H., Jendrossek V., Riehle A., von Kurthy G., Berger J., Schwarz H., Weller M., Kolesnick R., Gulbins E. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nature Med 2003, 9:322-330.
26. Balough K., McCubbin M., Weinberger M., Smits W., Ahrens R., Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995, 20:63-70.
27. Khan T.Z., Wagener J.S., Bost T., Martinez J., Accurso F.J., Riches D.W. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151:1075-1082.
28. Rosenfeld M., Gibson R.L., McNamara S., Emerson J., Burns J.L., Castile R., Hiatt P., McCoy K., Wilson C.B., Inglis A., Smith A., Martin T.R., Ramsey B.W. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001, 32:356-366.
29. Stone P.J., Konstan M.W., Berger M., Dorkin H.L., Franzblau C., Snider G.L. Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med 1995, 152:157-162.
30. Goldstein W., Döring G. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis 1986, 134:49-56.
31. Cocci F., Miniati M., Monti S., Cavarra E., Gambelli F., Battolla L., Lucattelli M., Lungarella G. Urinary desmosine excretion is inversely correlated with the extent of emphysema in patients with chronic obstructive pulmonary disease. Intern J Biochem Cell Biol 2002, 34:594-604.
32. Chapman H.A. Disorders of lung matrix remodeling. J Clin Invest 2004, 113:148-157.
33. Tetley T.D. Macrophages and the pathogenesis of COPD. Chest 2002, 121:156S-159S.
34. Taggart C.C., Greene C.M., Smith S.G., Levine R.L., PBJr McCray, O'Neill S., McElvaney N.G. Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J Immunol 2003, 171:931-937.
35. Ratjen F., Hartog C.M., Paul K., Wermelt J., Braun J. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax 2002, 57:930-934.
36. Power C., O'Connor C.M., McFarlane D., O'Mahoney S., Gaffney K., Hayes J., FitzGerald M.X. Neutrophil collagenase in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 1994, 50:818-822.
37. Delacourt C., Le Bourgeois M., D'Ortho M.P., Doit C., Scheinmann P., Navarro J., Harf A., Hartmann D.J., Lafuma C. Imbalance between 95kDa type IV collagenase and tissue inhibitor of metalloproteinases in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med 1995, 52:765-774.
38. Hilliard T.N., Regamey N., Shute J.K., Nicholson A.G., Alton E.W.F.W., Bush A., Davies J.C. Airway remodelling in children with cystic fibrosis. Thorax 2007, 62:1074-1080.
39. Di A., Brown M.E., Deriy L.V., Li C., Szeto F.L., Chen Y., Huang P., Tong J., Naren A.P., Bindokas V., Palfrey H.C., Nelson D.J. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nature Cell Biol 2006, 8:933-944.
40. Bjarnsholt T., Jensen P.O., Fiandaca M.J., Pedersen J., Hansen C.R., Andersen C.B., Pressler T., Givskov M., Hoiby N. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Ped Pulmonol 2009, 44:547-558.
41. Tirouvanziam R., Khazaal I., Peault B. Primary inflammation in human cystic fibrosis small airways. Am J Physiol 2002, 283:L445-L451.
42. Machen T.E. Innate immune response in CF airway epithelia: hyperinflammatory?. Am J Physiol 2006, 291:C218-C230.
43. Becker M.N., Sauer M.S., Muhlebach M.S., Hirsh A.J., Wu Q., Verghese M.W., Randell S.H. Cytokine secretion by cystic fibrosis airway epithelial cells. Am J Respir Crit Care Med 2004, 169:645-653.
44. Grubb B.R., Boucher R.C. Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiological Rev 1999, 79(suppl 1):S193-S214.
45. Petrache I., Natarajan V., Zhen L., Medler T.R., Richter A.T., Cho C., Hubbard W.C., Berdyshev E.V., Tuder R.M. Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nature Med 2005, 11:491-498.
46. Sreenivasan Y., Sarkar A., Manna S.K. Oleandrin suppresses activation of nuclear transcription factor-kappa B and activator protein-1 and potentiates apoptosis induced by ceramide. Biochem Pharmacol 2003, 66:2223-2239.
47. Yang Z., Costanzo M., Golde D.W., Kolesnick R.N. Tumor necrosis factor activation of the sphingomyelin pathway signals nuclear factor kappa B translocation in intact HL-60 cells. J Biol Chem 1993, 268:20520-20523.
48. Dbaibo G.S., Hannun Y.A. Signal transduction and the regulation of apoptosis: roles of ceramide. Apoptosis 1998, 3:317-334.
49. Saadane A., Soltys J., Berger M. Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-kappa B activation, cytokine secretion, and persistent lung inflammation. J Allergy Clin Immunol 2006, 117:1163-1169.
50. Goldstein R.H., Poliks C.F., Pilch P.F., Smith B.D., Fine A. Stimulation of collagen formation by insulin and insulin-like growth factor I in cultures of human lung fibroblasts. Endocrinology 1989, 124:964-970.
51. Harrison N.K., Cambrey A.D., Myers A.R., Southcott A.M., Black C.M., du Bois R.M., Laurent G.J., McAnulty R.J. Insulin-like growth factor-I is partially responsible for fibroblast proliferation induced by bronchoalveolar lavage fluid from patients with systemic sclerosis. Clin Sci (London) 1994, 86:141-148.
52. Cao B., Guo Z., Zhu Y., Xu W. The potential role of PDGF, IGF-1, TGF-beta expression in idiopathic pulmonary fibrosis. Chin Med J 2000, 113:776-782.
53. Balfour-Lynn I.M., Klein N.J., Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 1997, 77:124-130.
54. Bisgaard H., Pedersen S.S., Nielsen K.G., Skov M., Laursen E.M., Kronborg G., Reimert C.M., Høiby N., Koch C. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997, 156:1190-1196.
55. McElvaney N.G., Hubbard R.C., Birrer P., Chernick M.S., Caplan D.B., Frank M.M., Crystal R.G. Aerosol α1-antitrypsin treatment for cystic fibrosis. Lancet 1991, 337:392-394.
56. McElvaney N.G., Nakamura H., Birrer P., Hebert C.A., Wong W.L., Alphonso M., Baker J.B., Catalano M.A., Crystal R.G. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992, 90. 1296-01.